Amaranth Medical Initiates Clinical Trial of the Second-Generation FORTITUDE Bioresorbable Drug-Eluting Scaffold
September 16, 2014 09:00 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA, Sept. 16, 2014 (GLOBE NEWSWIRE) -- Amaranth Medical, a
privately held medical device company, announced the initiation of
patient enrollment in multiple centers in Colombia, South...
Coronary Stents - Emerging Markets (Brazil, Russia, India, China, South Africa And South Korea), 2009-2015
October 23, 2013 10:01 ET
|
Research and Markets
Dublin, Oct. 23, 2013 (GLOBE NEWSWIRE) -- Dublin - Research and Markets
(http://www.researchandmarkets.com/research/f9mkhm/coronary_stents)
has announced the addition of the
"Coronary...
Global Coronary Stents - Market Growth Analysis, 2009-2015
October 04, 2013 09:31 ET
|
Research and Markets
Dublin, Oct. 4, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/thlsqn/global_coronary)
has announced the addition of the
"Global Coronary Stents - Market...
![American Heart Association Logo](/news-release/logo/213500/0/213500.jpg?lastModified=12%2F09%2F2016%2022%3A55%3A27&size=2)
Bypass Surgery More Cost Effective Than Stents for Diabetics Long Term
November 04, 2012 21:12 ET
|
American Heart Association
Study Highlights:
Bypass surgery is more cost effective than drug-covered stents for people with diabetes who have multiple clogged heart arteries.
Initially, bypass surgery may cost more...
![American Heart Association Logo](/news-release/logo/213500/0/213500.jpg?lastModified=12%2F09%2F2016%2022%3A55%3A27&size=2)
Bypass Surgery Significantly Better Than Stents for Treating Multiple Blockages in Diabetics
November 04, 2012 07:58 ET
|
American Heart Association
Study Highlights:
Patients with diabetes who have multiple clogged heart arteries fared significantly better when treated with bypass surgery than drug-covered stents.
These patients were...